• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Covidien logs first patient in Iliac stent studies | Research Roundup

Covidien logs first patient in Iliac stent studies | Research Roundup

August 8, 2011 By MassDevice staff

Covidien

Covidien Plc. (NYSE:COV) enrolled the first patients into its two Iliac stent trials, Durability and Visibility.

The trials will each enroll 75 patients at up 20 centers in Europe and the U.S. in order to test the safety and effectiveness of Mansfield, Mass.-based Covidien’s Iliac stent systems for patients with peripheral arterial disease.

Both studies have started in Belgium, enrolling patients at AZ St-Blasius in Dendermonde and Imelda Hospital in Bonheiden.

Covidien ranked 9th on the MassDevice Big 100 list of the world’s largest medical device companies.

The Durability trial will test the Protege EverFlex self-expanding stent with delivery technology, and the Visibility study will test the Visi-Pro balloon expandable stent systems.

Visi-Pro and Protege are already available in the U.S. as treatments for malignant neoplasts in the biliary tree, according to the press release, but the studies hope to expand the indications to PAD treatment in the iliac arteries.

Listen to our exclusive podcast of MassDevice publisher Brian Johnson’s intimate interview with Covidien CEO Joe Almeida.

M and A Roundup

Here’s a roundup of recent clinical trial and scientific study news:

  • Artificial lungs inch closer to the real thing by casting aside oxygen tanks
    The next generation of artificial lungs may be able to use air instead of pure oxygen that current man-made lungs require, according to researchers at Case Western Reserve University in Cleveland, Ohio. The device is still years away from human use, but researchers say that by the time it’s ready it’ll only be about the size of a human lung, or around 6 inches by 6 inches by 4 inches.
    Read more
  • Biotronik completes enrollment in 4Ever study, begins enrollment in stent study
    Biotronik AG has been busy with trials in the last month, announcing closed enrollment of its 4Ever study and opening enrollment for its BioFlow II study. The 4Ever study enrolled 120 patients into a physician-initiated trial of the Switzerland-based company’s Astron Pulsar and Pulsar-18 stents in treatment of superficial femoral artery lesions. The stent trial will study about 440 patients to compare Biotronik’s Orsiro drug-eluting stent to Abbott’s (NYSE:ABT) Xience Prime stent.
    Read more
  • Heart pumps are okay for the elderly

    Left ventricular assist devices led to better quality of life in patients over the age of 70, according to a study published in the June issue of the
    Journal of the American College of Cardiology. Patients were implanted with Thoratec Corp.’s (NSDQ:THOR) HeartMate II LVAD, which won FDA clearance in April 2008.
    Read more
  • Filed Under: News Well, Research & Development, Stents, Structural Heart Tagged With: Abbott, Artificial Organs, Biotronik, Covidien

    More recent news

    • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
    • PharmaSens, SiBionics collab on all-in-one insulin patch pump
    • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
    • Anaconda Biomed wins CE mark for funnel catheter
    • FDA approves Neuspera neuromod for urinary incontinence

    Primary Sidebar

    “md
    EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
    Get the latest med device regulatory, business and technology news.

    DeviceTalks Weekly

    See More >

    MEDTECH 100 Stock INDEX

    Medtech 100 logo
    Market Summary > Current Price
    The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
    MDO ad

    Footer

    MASSDEVICE MEDICAL NETWORK

    DeviceTalks
    Drug Delivery Business News
    Medical Design & Outsourcing
    Medical Tubing + Extrusion
    Drug Discovery & Development
    Pharmaceutical Processing World
    MedTech 100 Index
    R&D World
    Medical Design Sourcing

    DeviceTalks Webinars, Podcasts, & Discussions

    Attend our Monthly Webinars
    Listen to our Weekly Podcasts
    Join our DeviceTalks Tuesdays Discussion

    MASSDEVICE

    Subscribe to MassDevice E-Newsletter
    Advertise with us
    About
    Contact us

    Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
    The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

    Privacy Policy